Empat Launches Empat School to Train Next-Gen Full-Stack & Flutter Developers

Kyiv, Ukraine–(Newsfile Corp. – December 11, 2025) – Custom software and mobile app development agency Empat has announced it is now accepting applications for Empat School, a complimentary online program designed to train aspiring developers that will commence on January 5, 2026. Empat School banner To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10587/277569_5e906064b4024b3a_001full.jpg […]

Gut health à la CAR T

Ever notice that as you get older, some foods no longer sit with you the same? This could be due to a breakdown of the intestinal epithelium, a single layer of cells that forms the organ's lining. The intestine plays a crucial role in many health functions, including digestion. Under normal conditions, the entire intestinal

Patria Investments Announces Acquisition of RBR Gestão, adding US$ 1.5 bn in Listed Real Estate Investment Trusts (“REITs”) in Brazil

(NASDAQ:PAX), GRAND CAYMAN, Cayman Islands, Dec. 11, 2025 (GLOBE NEWSWIRE) — Patria Investments Limited (“Patria”) (NASDAQ: PAX), a global alternative asset manager, announced today the agreement to acquire RBR Gestão de Recursos Ltda. (“RBR Gestão”), which, after internal corporate reorganization, will hold approximately US$ 1.5 bn of listed Real Estate Investment Trusts (“REITs”). RBR Gestão

InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904

(NASDAQ:IFRX), JENA, Germany, Dec. 11, 2025 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the World Health Organization (WHO) has granted the international nonproprietary (generic) name (INN) of “izicopan” to the Company for its orally available C5aR inhibitor, formerly known as INF904,

Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day

(NASDAQ:ROIV),(NasdaqGM:ROIVW), Roivant enters new phase of corporate journey with 3+ launches, 4+ NDA/BLA filings, 8+ pivotal and 3+ proof-of-concept study readouts expected over the next three years Highlighting clinical execution, Roivant announces positive updates to timing guidance across four key programs: Brepocitinib NDA filing in dermatomyositis (DM) now expected in early calendar year 2026; commercial

Domestic Metals Announces Gord Neal as CEO

(TSX-V:DMCU),(OTC US:DMCUF),(OTCQB:DMCUF),(Boerse Frankfurt – Freiverkehr:03E0.F), VANCOUVER, British Columbia, Dec. 11, 2025 (GLOBE NEWSWIRE) — Domestic Metals Corp. (the “Company” or “Domestic”) – (TSXV: DMCU; OTCQB: DMCUF; FSE: 03E) announces the appointment of Gordon Neal as Chief Executive Officer of the Company. Mr. Neal has had a notable and successful career in the mining and resource

Caliber Commences LINK Staking to Support Chainlink Node Program

(NASDAQ:CWD), SCOTTSDALE, Ariz., Dec. 11, 2025 (GLOBE NEWSWIRE) — Caliber (Nasdaq: CWD), a diversified real estate and digital asset management platform, announced today that it has staked 75,000 LINK tokens directly with a leading Chainlink node operator. This marks the company's first direct participation in the core infrastructure that secures the Chainlink Network. The initial

Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

(NasdaqGM:RYTM), –– BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy — — Promising results supportive of Phase 3, registrational trial of setmelanotide in PWS — — Company initiated Phase 1, Part D study

Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines

PALO ALTO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) — Autobahn Labs (“Autobahn”), a venture studio focused on transforming high-potential academic science into investable drug discovery and development programs, announced today a strategic partnership with global life sciences company Astellas Pharma Inc. (“Astellas”). The collaboration seeks to advance academic research and discoveries into novel therapeutics, providing

Beneficient Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price

(NASDAQ:BENF), DALLAS, Dec. 11, 2025 (GLOBE NEWSWIRE) — Beneficient (Nasdaq: BENF), a technology-enabled platform providing liquidity and related trust and custody services to holders of alternative assets, today announced a 1-for-8 reverse stock split (the “Reverse Stock Split”) of its Class A common stock, par value $0.001 per share (the “Class A Common Stock”), and

Scroll to Top